| Active substance | Amivantamab |
| Holder | Janssen-Cilag NV |
| Status | Running |
| Indication | in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 12/08/2024 |